<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684021</url>
  </required_header>
  <id_info>
    <org_study_id>579</org_study_id>
    <secondary_id>U01HL087318</secondary_id>
    <secondary_id>1 U01-HL-087318-01 (Project 1)</secondary_id>
    <nct_id>NCT00684021</nct_id>
  </id_info>
  <brief_title>Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)</brief_title>
  <official_title>Transplantation in Myocardial Infarction Evaluation (TIME) Protocol: A Phase II, Randomized, Controlled, Double-Blind Trial Evaluating the Effect of Timing on the Administration of Bone Marrow Mononuclear Cells (BMMNCs) Versus Placebo in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart attacks are a leading cause of death for both men and women in the United States. A
      heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot
      that has formed in one of the coronary arteries. If the clot becomes large enough, blood flow
      to the heart can be blocked almost completely and the heart muscle in that area can suffer
      permanent injury or death. Although a percutaneous coronary intervention (PCI) can be used to
      open up the blocked artery and restore blood flow to the heart muscle, there may be a
      significant amount of heart tissue that has been irreversibly damaged. Recent studies have
      shown that adult stem cells from bone marrow may be able to improve heart function after a
      heart attack. This study will evaluate the safety and effectiveness of using adult stem cells
      for improving heart function in people who have had a recent heart attack and a PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than 1 million Americans suffer a heart attack each year, resulting in about a 38%
      mortality rate. Although current treatments are able to stabilize the condition of the heart,
      none is able to restore heart function as it was prior to the heart attack. The permanent
      damage to the heart can lead to more severe problems, such as heart failure and irregular
      heartbeat, making the discovery of treatments to improve heart function after a heart attack
      important. Adult stem cells, which are immature cells that can become many different types of
      cells, may offer a potential means of reversing or preventing permanent damage caused by a
      heart attack. These specialized cells may have the ability to promote blood vessel growth,
      prevent cell death, and transform themselves into a number of tissues, including muscle.
      Recent studies have shown promise in using adult stem cells from bone marrow to reverse
      damage to the heart muscle caused by a heart attack, but more research is needed to assess
      the safety and effectiveness of stem cell use and to discover the best time to administer
      treatment. This study will evaluate the safety and effectiveness of placing adult stem cells
      into injured heart muscle for improving heart function in people who have had a recent heart
      attack and a PCI. Additionally, this study will help determine the best time to insert stem
      cells after a heart attack.

      Participation in this study will last 24 months. All participants will first undergo baseline
      assessments that will include a medical history, a physical exam, an electrocardiogram (ECG),
      blood draws, an echocardiogram, and a magnetic resonance imaging (MRI) test. Participants
      will then be assigned randomly to receive stem cells or placebo either 3 or 7 days after
      their heart attack. The morning of the stem cell or placebo infusion, participants will
      undergo a blood draw and a bone marrow aspiration procedure of the hip bone to collect the
      stem cells. Later the same day, either stem cells or placebo will be infused through a
      catheter and into the damaged area of the heart.

      For the first 24 hours following the infusion, participants will be asked to wear a small ECG
      machine called a Holter monitor. Participants will also be asked to record their temperature
      twice a day for a month after the infusion. Participants will return for follow-up visits at
      Months 1, 3, 6, 12, and 24 and will repeat many of the baseline assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Left Ventricular Function</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Left ventricular ejection fraction (global) as assessed via cardiac MRI. Values reported represent the change in Global EF from baseline to six months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Regional Left Ventricular Function (Infarct Zone Wall Motion)</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>One of two calculated values of regional left ventricular function as assessed via cardiac MRI. The infarct zone is defined as the cMRI segments with the largest 2 signal intensity enhancement measures with gadolinium (using a 17-segment model).Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Regional Left Ventricular Function (Border Zone Wall Motion)</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Two of two calculated values of regional left ventricular function assessed via cardiac MRI. The border zone is defined as those regions adjacent to the infarct zone in which the cMRI signal intensity enhancement were in the 10%-75% range. Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clincal and Safety Outcomes</measure>
    <time_frame>Measured from baseline to six months.</time_frame>
    <description>Number of events -death, reinfarction, repeat revascularizations (target and nontarget vessels) hospitalizations for heart failure, ICD placements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Left ventricular mass (LV mass. Values reported represent the change in LV mass from baseline to six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Volume Index</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Left ventricular end diastolic volume index. Values reported represent the change in LV end diastolic index from baseline to six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Systolic Volume Index</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Left ventricular end systolic volume index. Values reported represent the change in LV end systolic volume index from baseline to six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct Volume</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Infarct volume(mL). Values reported represent the change in infarct volume from baseline to six months.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adult stem cells</intervention_name>
    <description>One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Adult autologous stem cells</other_name>
    <other_name>Bone marrow mononucleated cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One time infusion of 30 ml of HSA (5%)</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>HSA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Patients at least 21 years of age

          2. Patients with first acute MI with successful primary percutaneous coronary
             intervention (PCI) in an artery at least 2.5 mm in diameter within 24 hours of onset
             of symptoms.

          3. No contraindications to undergoing cell therapy procedure within three to seven days
             following AMI and PCI.

          4. Hemodynamic stability as defined as no requirement for IABP, inotropic or blood
             pressure supporting medications.

          5. Ejection fraction following reperfusion with PCI &lt;=45% as assessed by
             echocardiography.

          6. Consent to protocol and agree to comply with all follow-up visits and studies.

          7. Women of child bearing potential willing to use an active form of birth control.

        Exclusion criteria

        Patients will be excluded from the study if they meet any of the following conditions:

          1. History of sustained ventricular arrhythmias not related to their AMI (evidenced by
             previous holter monitoring and/or medication history for sustained ventricular
             arrhythmias in patient's medical chart).

          2. Require CABG or PCI due to the presence of residual coronary stenosis &gt;70% luminal
             obstruction in the non-infarct related vessel (Additional PCI of non-culprit vessels
             may be performed prior to enrollment).

          3. History of any malignancy within the past five years excluding non-melanoma skin
             cancer or cervical cancer in-situ.

          4. History of chronic anemia (hemoglobin (Hb) &lt;9.0 mg/dl).

          5. History of thrombocytosis (platelets &gt;500k).

          6. History of thrombocytopenia in the absence of recent evidence that platelet counts are
             normal

          7. Known history of elevated INR (PT) or PTT.

          8. Life expectancy less than one year.

          9. History of untreated alcohol or drug abuse.

         10. Currently enrolled in another investigational drug or device trial

         11. Previous CABG.

         12. Previous MI resulting in LV dysfunction (LVEF &lt;55%)

         13. History of stroke or transient ischemic attack (TIA) within the past six months.

         14. History of severe valvular heart disease (aortic valve area &lt;1.0 cm2 or &gt;3+ mitral
             regurgitation).

         15. Pregnancy or breast feeding

         16. Subjects with a known history of HIV, or has active hepatitis B,active hepatitis C, or
             active TB

         17. Patients with active inflammatory or autoimmune disease on chronic immuno-suppressive
             therapy.

         18. Contraindications to cMRI.

         19. Previous radiation to the pelvis with white blood cell count (WBC) and platelet counts
             below hospital specific normal values.

         20. Women child bearing potential not willing to practice an active form of birth control.

         21. Chronic liver disease that might interfere with survival or treatment with cell
             therapy.

         22. Chronic renal insufficiency as defined by a creatinine ≥ 2.0 mg/dL or requires chronic
             dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Simari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Cell Therapy Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida-Department of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cctrn.org</url>
    <description>Click here for more information on this study at the Cardiovascular Cell Therapy Research Network (CCTRN)</description>
  </link>
  <link>
    <url>http://www.vascularbiomed.iu.edu/</url>
    <description>Click here for more information about this study at the Indiana Center for Vascular Biology and Medicine</description>
  </link>
  <link>
    <url>http://www.nhlbi.nih.gov/</url>
    <description>Click here for the National Heart, Lung, and Blood Institute</description>
  </link>
  <reference>
    <citation>Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J. 2009 Sep;158(3):356-63. doi: 10.1016/j.ahj.2009.06.009. Epub 2009 Jul 23. Erratum in: Am Heart J. 2009 Dec;158(6):1045. Vaughn, Douglas E [corrected to Vaughan, Douglas E].</citation>
    <PMID>19699857</PMID>
  </reference>
  <reference>
    <citation>Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy. 2010 Sep;12(5):684-91. doi: 10.3109/14653249.2010.487900.</citation>
    <PMID>20524773</PMID>
  </reference>
  <reference>
    <citation>Zierold C, Carlson MA, Obodo UC, Wise E, Piazza VA, Meeks MW, Vojvodic RW, Baraniuk S, Henry TD, Gee AP, Ellis SG, Moyé LA, Pepine CJ, Cogle CR, Taylor DA. Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. Am Heart J. 2011 Dec;162(6):973-80. doi: 10.1016/j.ahj.2011.05.024.</citation>
    <PMID>22137069</PMID>
  </reference>
  <results_reference>
    <citation>Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012 Dec 12;308(22):2380-9. Erratum in: JAMA. 2015 Jul 7;314(1):86. JAMA. 2013 Jan 23;309(4):343.</citation>
    <PMID>23129008</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>February 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Dr Lemuel A Moye III</investigator_full_name>
    <investigator_title>Professor - School of Public Health</investigator_title>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Global Left Ventricular Ejection Fraction</keyword>
  <keyword>Regional Left Ventricular Ejection Fraction</keyword>
  <keyword>Left Ventricular Mass</keyword>
  <keyword>Infarct Size</keyword>
  <keyword>End Systolic Volume</keyword>
  <keyword>End Diastolic Volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment took place at five Network centers and their associated satellite facilities between July 2008 and November 2011. The main centers are located in Ohio, Texas, Florida, Minnesota, and Tennessee. Study brochures, patient informational DVDs, and clinical trials.gov were among the tools used for recruitment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Day 3 Stem Cell Arm</title>
          <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
        </group>
        <group group_id="P2">
          <title>Day 3 Placebo Arm</title>
          <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
        </group>
        <group group_id="P3">
          <title>Day 7 Stem Cell Arm</title>
          <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
        </group>
        <group group_id="P4">
          <title>Day 7 Placebo Arm</title>
          <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>MRI Contraindicated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>MRI not performed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Day 3 Stem Cell Arm</title>
          <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
        </group>
        <group group_id="B2">
          <title>Day 3 Placebo Arm</title>
          <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
        </group>
        <group group_id="B3">
          <title>Day 7 Stem Cell Arm</title>
          <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
        </group>
        <group group_id="B4">
          <title>Day 7 Placebo Arm</title>
          <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="10.8"/>
                    <measurement group_id="B2" value="57.0" spread="12.4"/>
                    <measurement group_id="B3" value="58.2" spread="11.3"/>
                    <measurement group_id="B4" value="57.0" spread="8.0"/>
                    <measurement group_id="B5" value="56.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Left Ventricular Function</title>
        <description>Left ventricular ejection fraction (global) as assessed via cardiac MRI. Values reported represent the change in Global EF from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in Global EF from baseline to six months.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Left Ventricular Function</title>
          <description>Left ventricular ejection fraction (global) as assessed via cardiac MRI. Values reported represent the change in Global EF from baseline to six months.</description>
          <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in Global EF from baseline to six months.</population>
          <units>percentage of ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="11.0"/>
                    <measurement group_id="O2" value="4.4" spread="10.6"/>
                    <measurement group_id="O3" value="2.8" spread="9.7"/>
                    <measurement group_id="O4" value="1.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.959</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Stem cell treatment arm combined (Day 3 and Day7); placebo group also combined.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clincal and Safety Outcomes</title>
        <description>Number of events -death, reinfarction, repeat revascularizations (target and nontarget vessels) hospitalizations for heart failure, ICD placements</description>
        <time_frame>Measured from baseline to six months.</time_frame>
        <population>All randomized patients were followed for clinical outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Clincal and Safety Outcomes</title>
          <description>Number of events -death, reinfarction, repeat revascularizations (target and nontarget vessels) hospitalizations for heart failure, ICD placements</description>
          <population>All randomized patients were followed for clinical outcomes.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Clinical and Safety Outcomes including death, reinfarction, repeat revascularization, hospitalization for heart failure and ICD placement. The relative incidences of events are compared between the active and placebo groups.However the paucity of events precluded a reliable time to event analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Mass</title>
        <description>Left ventricular mass (LV mass. Values reported represent the change in LV mass from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in LV mass from baseline to six months.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Mass</title>
          <description>Left ventricular mass (LV mass. Values reported represent the change in LV mass from baseline to six months.</description>
          <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in LV mass from baseline to six months.</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="22.8"/>
                    <measurement group_id="O2" value="-13.2" spread="30.6"/>
                    <measurement group_id="O3" value="-16.3" spread="16.7"/>
                    <measurement group_id="O4" value="-20.7" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 3 Stem Cell Arm and Day 7 Stem Cell Arm were combined and compared to the combination of Day 3 Placebo and Day 7 Placebo arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.585</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.2</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End Diastolic Volume Index</title>
        <description>Left ventricular end diastolic volume index. Values reported represent the change in LV end diastolic index from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in LV end diastolic index from baseline to six months.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>End Diastolic Volume Index</title>
          <description>Left ventricular end diastolic volume index. Values reported represent the change in LV end diastolic index from baseline to six months.</description>
          <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in LV end diastolic index from baseline to six months.</population>
          <units>mL/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="18.5"/>
                    <measurement group_id="O2" value="11.7" spread="19.8"/>
                    <measurement group_id="O3" value="13.3" spread="19.5"/>
                    <measurement group_id="O4" value="9.7" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 3 Stem Cell Arm and Day 7 Stem Cell Arm were combined and compared to the combination of Day 3 Placebo and Day 7 Placebo arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.831</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End Systolic Volume Index</title>
        <description>Left ventricular end systolic volume index. Values reported represent the change in LV end systolic volume index from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in LV end systolic volume index from baseline to six months.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>End Systolic Volume Index</title>
          <description>Left ventricular end systolic volume index. Values reported represent the change in LV end systolic volume index from baseline to six months.</description>
          <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in LV end systolic volume index from baseline to six months.</population>
          <units>mL/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="15.0"/>
                    <measurement group_id="O2" value="4.1" spread="16.5"/>
                    <measurement group_id="O3" value="6.2" spread="17.4"/>
                    <measurement group_id="O4" value="4.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 3 Stem Cell Arm and Day 7 Stem Cell Arm were combined and compared to the combination of Day 3 Placebo and Day 7 Placebo arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.817</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infarct Volume</title>
        <description>Infarct volume(mL). Values reported represent the change in infarct volume from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in infarct volume from baseline to six months.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Infarct Volume</title>
          <description>Infarct volume(mL). Values reported represent the change in infarct volume from baseline to six months.</description>
          <population>Only participants with both baseline and 6 month MRI images available are included.
Values reported represent the change in infarct volume from baseline to six months.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="18.4"/>
                    <measurement group_id="O2" value="-7.7" spread="23.4"/>
                    <measurement group_id="O3" value="-13.6" spread="18.8"/>
                    <measurement group_id="O4" value="-5.3" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 3 Stem Cell Arm and Day 7 Stem Cell Arm were combined and compared to the combination of Day 3 Placebo and Day 7 Placebo arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.272</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>3.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Regional Left Ventricular Function (Infarct Zone Wall Motion)</title>
        <description>One of two calculated values of regional left ventricular function as assessed via cardiac MRI. The infarct zone is defined as the cMRI segments with the largest 2 signal intensity enhancement measures with gadolinium (using a 17-segment model).Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and 6 month MRI images available are included. Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Left Ventricular Function (Infarct Zone Wall Motion)</title>
          <description>One of two calculated values of regional left ventricular function as assessed via cardiac MRI. The infarct zone is defined as the cMRI segments with the largest 2 signal intensity enhancement measures with gadolinium (using a 17-segment model).Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.</description>
          <population>Only participants with both baseline and 6 month MRI images available are included. Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="5.9"/>
                    <measurement group_id="O2" value="2.4" spread="5.3"/>
                    <measurement group_id="O3" value="1.2" spread="4.9"/>
                    <measurement group_id="O4" value="2.8" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Stem cell treatment arm combined (Day 3 and Day7); placebo group also combined.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15</ci_lower_limit>
            <ci_upper_limit>1000</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Regional Left Ventricular Function (Border Zone Wall Motion)</title>
        <description>Two of two calculated values of regional left ventricular function assessed via cardiac MRI. The border zone is defined as those regions adjacent to the infarct zone in which the cMRI signal intensity enhancement were in the 10%-75% range. Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 3 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Day 3 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
          </group>
          <group group_id="O3">
            <title>Day 7 Stem Cell Arm</title>
            <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
          </group>
          <group group_id="O4">
            <title>Day 7 Placebo Arm</title>
            <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Left Ventricular Function (Border Zone Wall Motion)</title>
          <description>Two of two calculated values of regional left ventricular function assessed via cardiac MRI. The border zone is defined as those regions adjacent to the infarct zone in which the cMRI signal intensity enhancement were in the 10%-75% range. Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.</description>
          <population>Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="9.3"/>
                    <measurement group_id="O2" value="4.3" spread="8.7"/>
                    <measurement group_id="O3" value="4.2" spread="8.3"/>
                    <measurement group_id="O4" value="4.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.777</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Stem cell treatment arm combined (Day 3 and Day7); placebo group also combined.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events reported are from Randomization Date to the 6 month endpoint data collection window (i.e. 210 days post intervention)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Day 3 Stem Cell Arm</title>
          <description>Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).</description>
        </group>
        <group group_id="E2">
          <title>Day 3 Placebo Arm</title>
          <description>Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.</description>
        </group>
        <group group_id="E3">
          <title>Day 7 Stem Cell Arm</title>
          <description>Participants will receive active adult stem cell infusion 7 days after PCI.</description>
        </group>
        <group group_id="E4">
          <title>Day 7 Placebo Arm</title>
          <description>Participants will receive placebo infusion (5% HSA) 7 days after PCI.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>New/Worsening Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Groin bruising/bleeding</sub_title>
                <description>Groin bruising or bleeding at site of catheter insertion</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The choice of Day 3 or Day 7 as randomization points while based on the literature were nevertheless somewhat arbitrary. cMR-baseed ejection fractions tended to be high.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lemuel Moye, MD, PhD</name_or_title>
      <organization>UT-Houston School of Public Health</organization>
      <phone>713-500-9518</phone>
      <email>Lemmoye@msn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

